Gene therapy for osteoarthritis

Steven C. Ghivizzani, Christopher H. Evans

Research output: Chapter in Book/Report/Conference proceedingChapter


Osteoarthritis (OA) is an incurable, chronic, painful, debilitating joint disease characterized primarily by the gradual erosion of protective articular cartilage. Although joint damage contributes to the onset of OA, the continued synthesis of inflammatory cytokines, such as interleukin-1, by synovial cells and chondrocytes is thought to drive the progression of disease. Numerous naturally occurring proteins have been identified with the potential to block inflammatory processes, or alternatively, stimulate the repair of damaged cartilage. Problems lie in the lack of effective methods of delivery, as most proteins have limited half-lives in vivo. Through the use of gene therapy applications, exogenous transgenes can be delivered to cells and tissues of arthritic joints, thereby redirecting their biology for sustained, local synthesis of therapeutic transgene products. A wide variety of transgenes and methods of delivery are currently under investigation for their capacity to block ongoing inflammation or stimulate repair and regeneration of cartilage tissues in OA.

Original languageEnglish (US)
Title of host publicationGlutamate-based Therapies for Psychiatric Disorders
PublisherSpringer Basel
Number of pages22
ISBN (Print)9783034602402
StatePublished - Jan 1 2010

Publication series

NameMilestones in Drug Therapy
ISSN (Print)2296-6056
ISSN (Electronic)2296-6064

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology, Toxicology and Pharmaceutics (miscellaneous)


Dive into the research topics of 'Gene therapy for osteoarthritis'. Together they form a unique fingerprint.

Cite this